Nektar Therapeutics
NASDAQ · NKTR·San Francisco, CA·Small-cap·Phase 2
Clinical-stage biotech developing rezpegaldesleukin (REZPEG, NKTR-358), a first-in-class regulatory T cell stimulator for autoimmune and inflammatory diseases. Phase 2b programs in atopic dermatitis and alopecia areata; Phase 2 in Type 1 diabetes.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Nektar Therapeutics Corporate Presentation | Corporate overview | April 15, 2026 | 49 |